Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ghia

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Hematology & Oncology|February 22, 2026
UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignanciesCarmela Dell'Aversana, G Sgueglia, C Massaro, et al.
Frontiers in Immunology|September 8, 2025
Conventional and non-conventional antigen-binding sites promote the development and function of chronic lymphocytic leukemia stereotyped subset #4 clonesYun Liu, Dzmitry Padhorny, Rosa Catera, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|April 6, 2013
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2J C Strefford, L-A Sutton, P Baliakas, et al.
Leukemia|January 7, 2012
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implicationsV Bikos, N Darzentas, A Hadzidimitriou, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
American Journal of Hematology|January 24, 2024
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLLA Campanella, A Capasso, S Heltai, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Leukemia|December 8, 2015
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL studyA C Rawstron, C Fazi, A Agathangelidis, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Hematology & Oncology|February 22, 2026
UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignanciesCarmela Dell'Aversana, G Sgueglia, C Massaro, et al.
Frontiers in Immunology|September 8, 2025
Conventional and non-conventional antigen-binding sites promote the development and function of chronic lymphocytic leukemia stereotyped subset #4 clonesYun Liu, Dzmitry Padhorny, Rosa Catera, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|April 6, 2013
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2J C Strefford, L-A Sutton, P Baliakas, et al.
Leukemia|January 7, 2012
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implicationsV Bikos, N Darzentas, A Hadzidimitriou, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
American Journal of Hematology|January 24, 2024
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLLA Campanella, A Capasso, S Heltai, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Leukemia|December 8, 2015
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL studyA C Rawstron, C Fazi, A Agathangelidis, et al.
Pageof 5